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Summary
The abscopal effect is a phenomenon that describes the systemic antitumor response that can occur as a result of a lo-
calized radiotherapy. Although sporadic cases of abscopal effect have been reported since 1960’s, the number of reported 
cases are significantly increasing in the immunotherapy era. Immunotherapy seems to enhance the immunogenic effects of 
radiotherapy, thus increasing systemic antitumor response. Although combination of radiotherapy and immunotherapy is 
a promising strategy in the treatment of metastatic cancers, many questions regarding the optimal treatment remain unan-
swered. Increasing number of ongoing studies will hopefully provide answers to these questions, enabling the utilization of 
this strategy in systemic anticancer treatment.
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INTRODUCTION
Ever since it was first introduced into the 
treatment of cancer, radiotherapy has been uti-
lized predominantly in the local treatment of can-
cer. Its effects can be seen mainly within the irradi-
ated volume, with seemingly no effect on the cells 
and tissues outside of the treated area. Because of 
this, radiotherapy has found its place in the pri-
mary, neoadjuvant and adjuvant treatment of 
many sites of localized cancers, as well as pallia-
tive treatment of cancer metastases.
Lately, based on a series of case reports and 
further prompted by promising results of preclini-
cal and clinical studies, a new question has risen: 
can radiotherapy be used not only for locoregion-
al treatment, but as an active treatment of meta-
static disease?
In 1953. Mole was first to use the word ab-
scopal. He defined it as at a distance from the 
 irradiated volume, but within the same organism (1). 
The word itself is derived from the Latin prefix ab, 
which means away from, and Greek word scopus, 
which means target. Essentially, the term abscopal 
effect refers to an effect of certain treatment occur-
ring outside of the treatment field. Over the course 
of the last sixty years, number of case reports de-
scribed regression and even disappearance of dis-
tant metastases following radiation treatments of 
a single site. While cases varied in patient age, 
gender and tumor biology, it was clear that absco-
pal effect occurred mainly in immunogenic tu-
mors, such as melanoma, renal cell carcinoma, 
lung adenocarcinoma, lymphomas and leukemias 




The recent years have brought rapid devel-
opment of immunotherapy (reviewed in 3,4). New 
drugs which modulate the immune system are 
progressively used not only in immunogenic tu-
mors, such as melanoma (5), but also in lung can-
cer (6), esophageal, gastric and even colorectal 
cancer (7). It should be noted that head and neck 
squamous cell cancer, cervical cancer, colorectal 
cancer, and lung squamous cell cancer are also 
cancers with high T-cell infiltration scores, which 
suggests the possibility of efficacy of combined 
immunotherapy and radiotherapy treatment.
This has once again brought light on the ab-
scopal effect, prompting questions whether im-
munotherapy can potentially trigger abscopal ef-
fect of radiotherapy.
THE MECHANISM OF ABSCOPAL EFFECT
Radiation induces cell death via a specific 
process known as immunogenic cell death. During 
this process a number of immunogenic factors, 
such as DAMPs (damage-associated molecular pat-
terns), are released. DAMPs include ATP (adenos-
ine triphosphate), HMGB1 (high mobility group box 1) 
protein and calreticulin [8]. More specifically, dur-
ing immunogenic cell death calreticulin is translo-
cated to the cell surface, where is recognized and 
processed by dendritic cells (DCs). Mature DCs 
present tumor antigens to cytotoxic T lympho-
cytes (CTLs) and activate systemic antitumor re-
sponse (9). HMBG1 binds to Toll-like receptor 4 
(TLR4) on the surface of DCs, thus increasing anti-
gen presentation (10). ATP can also bind on recep-
tors on DCs, which results in interleukin 1β re-
lease (11). In addition to that, nucleic acids re-
leased from dead cells can act as ligands to 
Toll-like receptors (TLR3, 7, 8 and 9), which results 
in the release of various cytokines and interferons, 
and also enhances DC cross-priming (12).
Radiation also causes the upregulation of Fas 
molecule, a known trigger of apoptosis, as well as 
MHC I (major histocompatibility complex) complex, 
thus additionally increasing antigen presentation 
to the cytotoxic T lymphocytes ) (2,13).
It has been shown that the activation of cyto-
toxic T lymphocytes is a marker of radiosensitivi-
ty (14), and is a key in the development of the ab-
scopal effect (15).
Abscopal effect in clinical setting is a very 
rare event. This is probably due to the fact that ra-
diation can exhibit immunosuppressive effects, 
mainly through upregulation of TGFβ (transform-
ing growth factor beta), enhancement of regulatory 
T-cell representation, and recruitment of myeloid-
derived suppressor cells (16-19). These immuno-
suppressive effects in most cases likely counteract 
the immunostimulatory effects, which results in 
rarity of the abscopal effect.
However, the emergence and rapidly grow-
ing use of immunotherapy has brought into focus 
the potential of radiation therapy to induce sys-
temic antitumor responses, by tipping the scale in 
favor of immunostimulatory, rather than immu-
nosuppressive effects of radiation.
CLINICAL EVIDENCE OF THE ABSCOPAL 
EFFECT
In 2019 Dagoglu et al. published a systematic 
review of the reported cases of abscopal effect 
(disregarding the articles where current cytotoxic 
treatment was given with radiotherapy) between 
1960 and November 2018 and found 94 reported 
cases in 52 articles. It is notable that half of the re-
ported cases were treated with radiotherapy only, 
and were reported between 1969 and 2018, while 
the other half of the cases were treated with a com-
bination of radiotherapy and immunotherapy and 
reported between 2012 and 2018. The majority of 
the latter subgroup of patients were treated for 
non-small cell lung cancer and melanoma, while 
the other included Hodgkin’s lymphoma, gastric 
cancer, esophageal cancer, pancreatic cancer, re-
nal cell cancer and cervical cancer (large cell neu-
roendocrine histology) (20).
One of the more notable examples of absco-
pal effect in combined immune- and radiotherapy 
treatment was the report of a patient with meta-
static melanoma treated with ipilimumab as main-
tenance therapy who suffered from back pain as a 
result of a paraspinal mass. Total dose of 28.5 Gy 
in three fractions was administered to a paraspi-
nal mass. Four months after radiotherapy, CT 
scan showed not only paraspinal mass regression, 
but also regression of nonirradiated lesions in 
spleen and right hilar node. Stable, minimal dis-
ease persisted even after 10 months (21). Later re-
port showed a complete regression of primary 
and metastatic lesions in a patient with metastatic 




CLINICAL TRIALS USING CHECKPOINT INHIBITORS IN COMBINATION WITH RADIOTHERAPY  
[ADAPTED FROM 28]
NCT Number Status Condition Intervention Characteristics






Number of patients developing grade 3 or higher toxicity; 
In-field and out of field (abscopal) response; 
The number of completed ESAS questionnaires;  
Biomarkers analyses









Incidence of adverse events; 
Abscopal response rate;
Maximum tolerated dose










Objective response rate; 
Overall survival; 
Abscopal effects rate









Local and distant control; 
Quality of life of the patients; 
Acute/late toxicities










Local and systemic response of detected metastases;
Adverse events;
Change of circulating immune cells of treated patients by deep 
immunophenotyping







Maximal tolerated dose that is associated with dose-limiting 
toxicity in 25% of patients;
Immunomonitoring; 
Preliminary anti-tumor activity (using the immune related 
response criteria)  
following ipilimumab combined with escalating doses  
of radiation








Maximum tolerated dose of combined treatment;
Abscopal response;
Local response; 







NCT Number Status Condition Intervention Characteristics






Progression-free survival (PFS) rate at 6 months;
PFS after radiotherapy/PFS during the previous line of treatment 
ratio; 
PFS by immune response criteria;
Overall survival; 
Objective response rate; 
Treatment toxicity; 
Quality of life;  
Rate of PET-CT at inclusion;
Treatment cost



























Objective response rate;  
Local control rate;  
Overall survival;  
Progression-free survival; 
Time to progression; 
New development of distant metastasis;
Quality of life;
Adverse effects;  
Predictive and prognostic biomarkers










Incidence of immune related adverse events















Progression-free survival (PFS) at 1 year; 
Grade 3-5 acute adverse events; 
Objective response rate; 
Local control rate at 2 years; 
Overall survival at 2 years; 
T cell clones in peripheral blood and T cell receptor repertoire;
PD-1, Ki-67 expression on T cell; 
PD-L1 expression on exosomes in peripheral blood and on 
circulating tumor cells











NCT Number Status Condition Intervention Characteristics










Change in circulating tumor deoxyribonucleic acid levels  
(by deep sequencing); 
Change in levels of immune markers;  
Incidence of acute and late grade 3-5 toxicity; 
Overall survival
NCT04221893 Not yet 
recruiting
Clinical stage IV 
esophageal, 
GEJ and gastric 
cancer
Radiotherapy Phase: not applicable 
Outcome Measures: 
Overall response rate;
Progression-free survival;  
Overall survival;
Tumor measurement change by RECIST or iRECIST; 
Local control in radiated lesion(s); 
Incidence of new metastatic lesions; 
Frequency of grade 3 or higher adverse events; 
Time to new systemic therapy













Incidence of adverse events;
Abscopal response rate;
Local control rate;
Overall response rate; 
Progression-free survival; 
Overall survival; 
Objective response per immune-related response criteria; 
Prognostic effect of PD-L1 expression; 
Prognostic effect of T-cell infiltration






Maximum tolerated dose of pembrolizumab in combination  
with radiotherapy;
Toxicity rate; 
Progression-free survival rates at 6 and 12 months  
(all and PDL-1 strong patients); 
Overall survival rates at 6 and 12 months  
(all and PDL-1 strong patients); 
Duration of clinical benefit;
Response rate comparison between squamous and non-
squamous cancers







Local response determined using CT imaging; 




Objective response by immune related response criteria;
Clinical benefit rate 
Table 1.
CONTINUED
therapy. Total dose of 54 Gy was given in three 
fractions (22). In another clinical study, 34 patients 
with castration-resistant prostate cancer were 
treated with ipilimumab and palliative bone ra-
diotherapy (one to three 8 Gy fractions). The re-
sults showed complete clinical response in one 
patient, while six other had stable disease (23).
Hiniker et al. have shown 13.6% complete re-
sponse rate in a prospective trial of combination 
ipilimumab plus radiotherapy in metastatic mela-
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noma patients (24), as opposed to 1.5% complete 
response rate reported in patients treated with ipi-
limumab only (25).
The efficacy of combined ipilimumab and ra-
diotherapy treatment was also studied in a phase 
I study of 22 patients with metastatic melanoma. 
The results showed that 36% of patients had par-
tial response or stable disease, while the rest had 
disease progression (26). It was later shown that 
the resistance to combination of radiotherapy and 
anti-CTLA4 treatment was partially linked to the 
upregulation of PD-L1 (27).
Currently, there are numerous ongoing clini-
cal trials investigating combinations of radiation 
and immunotherapy. Some of the ongoing trials 
are shown in Table 1.
As can be noted, most of the trials are phase I 
and II, and aim to investigate the potential syner-
gistic effects of radiation and immunotherapy in a 
myriad of cancers, including non-small cell lung 
cancer, head and neck cancer, colorectal cancer, 
esophageal, gastric and GEJ cancer, gynecological 
cancer, sarcoma and lymphoma. The most inter-
esting, however, may be a phase III French NIR-
VANA-Lung trial, which is examining the feasibil-
ity and efficacy of the combination of anti-PD-L1 
therapy and radiotherapy to advanced NSCLC. In 
this trial, 510 patients with stage IIIB-IV NSCLC 
are being randomized to receive immunotherapy 
(nivolumab, pembrolizumab or atezolizumab) or 
immunotherapy plus radiation (3D-CRT or SABR) 
to a total dose of 18 Gy in three fractions. Primary 
outcome of the trial is overall survival, which will 
be evaluated after a follow-up of 2 years. Local 
and distant disease control, tumor response, pro-
gression-free survival, quality of life and toxicities 
will be determined after a follow up of 6 months, 
1 year and 2 years, respectively.
THE OPTIMAL TIMING, DOSAGE AND 
FRACTIONATION OF RADIOTHERAPY
Currently, the optimal parameters of radio-
therapy to induce abscopal effect remain un-
known. The dosage, fractionation and timing 
seem to vary across different studies.
Some preclinical studies seem to favor fewer 
fractions. One study on murine melanoma showed 
better response after a single fraction of 8 Gy than 
five fractions of 4 Gy (29), while the other favored 
two fractions of 7.5 Gy over a single fraction of 15 
Gy (30).
Dewan et al. compared a single fraction of 20 
Gy, three fractions of 8 Gy and five fractions of 6 
Gy in combination with anti-CTLA4 antibody on 
a murine breast cancer, and reported that the frac-
tionated regimes had better antitumor effect than 
a single dose of 20 Gy [31]. One retrospective anal-
ysis of 47 metastatic melanoma patients showed a 
significant correlation between abscopal effect 
and fractionated radiation, particularly with frac-
tions equal and smaller than 3 Gy (32).
Currently, MD Anderson phase II trial 
(NCT02710253) is comparing different radiothera-
py regimes in inducing response rates in metastat-
ic patients who have been treated with immuno-
therapy within past 6 months. The regimes in-
clude 50 Gy in 4 fractions using stereotactic 
radiation or 60-70 Gy in 10 fractions, 20-30 Gy in 5 
fractions, or 30-45 Gy in 10-15 fractions using con-
ventional external-beam radiation. A phase I trial 
(NCT02406183), is comparing 24 Gy in 8 fractions 
using stereotactic radiation with 30 Gy in 10 frac-
tions and 36 Gy in 12 fractions using conventional 
external-beam radiation; in combination with ipi-
limumab for metastatic melanoma.
The optimal sequencing of immunotherapy 
and radiotherapy is also controversial. While it 
seems that combination of ipilimumab and radio-
therapy works best if given concurrently (31), dur-
valumab seems to be most effective if given after 
the chemoradiation (33).
One ongoing phase I study (NCT02826564) is 
evaluating the optimal sequencing of pembroli-
zumab and stereotactic body radiation in patients 
with urothelial carcinoma.
RADIOIMMUNOTHERAPY TOXICITY
There has been some concern that the combi-
nation of radiotherapy and immunotherapy may 
increase their respective toxicities. However, sev-
eral clinical trials have shown that this is not the 
case (33-39). One trial in metastatic melanoma, 
however, showed higher rates of radiation necro-
sis when radiotherapy was combined with ipilim-
umab (30% vs. 21%), while the other reported 
higher rate of treatment-related pulmonary toxic-
ity in comparison with pembrolizumab alone in 





Although abscopal effect is a phenomenon 
that has been known for many years, it has only 
recently been put under the spotlight, mostly due 
to the rapid advancements in immunotherapy. Al-
though some of the underlying mechanisms be-
hind this phenomenon have been understood, in-
cluding its immunogenic nature, there are still 
several unknown variables needed to be deter-
mined in order to maximize the abscopal response 
in clinical setting. These include dose-fraction-
ation regimes of radiotherapy, as well as determi-
nation of optimal treatment sequence. Increasing 
number of ongoing trials will hopefully give an-
swers to these questions, allowing utilization of 
local radiotherapy in achieving systemic antitu-
mor effects.
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Sažetak
APSKOPALNI UČINAK RADIOTERAPIJE: STARI KONCEPT U NOVOM DOBU
M. Mikulandra, I. Andrašek and L. Beketić-Orešković
Apskopalni učinak je fenomen koji opisuje sustavni antitumorski odgovor koji može nastati kao rezultat lokalizirane 
radioterapije. Premda su sporadični slučajevi prijavljivani još od 1960-tih godina, njihov je broj značajno porastao u eri imu-
noterapije. Čini se da imunoterapija stimulira imunogenične učinke radioterapije, pojačavajući na taj način sistemski antitu-
morski odgovor. Iako je kombinacija radioterapije i imunoterapije obećavajuća strategija u liječenju metastatskih tumora, još 
uvijek nemamo odgovore na brojna pitanja vezana za optimalni protokol liječenja. Sve veći broj istraživanja koja su u tijeku 
vjerojatno će dati odgovore ta neriješena pitanja, što će omogućiti korištenje ove strategije u sustavnom liječenju raka.
KLJUČNE RIJEČI: apskopalni učinak, radioterapija, imunoterapija
